anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVES: Controlled attenuation parameter (CAP) is a noninvasive and quantitative method to evaluate hepatic steatosis, which is not well evaluated in children. The aim of this study was to examine the diagnostic value of CAP for hepatic steatosis in children with obesity based on MR proton density fat fraction (PDFF).
METHODS: About 108 pediatric patients with nonalcoholic fatty liver disease (NAFLD) who were assessed for PDFF, CAP, and other laboratory results were enrolled. In this study, pediatric patients were separated for the obese group (n=80) and the severe obese group (n=28). Hepatic steatosis grades (0-3) were classified according to PDFF using cutoff values of 6.4 , 17.4, and 22.1 %.
RESULTS: There are significant differences in CAP between the obese and severe obese groups (p<0.05). CAP showed a good correlation with PDFF in pediatric patients with NAFLD for diagnosing hepatic steatosis using a cutoff value of 265 dB/m (p<0.001). Meanwhile, ALT significantly outperforms CAP in receiver-operating curve (ROC) analysis for diagnosing hepatic steatosis grades. The diagnostic accuracy of CAP for steatosis is 77.8 %, and the diagnostic accuracy of ALT for steatosis is 83.3 %.
CONCLUSIONS: While CAP holds promise as a diagnostic tool for pediatric NAFLD, its diagnostic performance warrants some caution. The potential of CAP is evident; however, ALT emerges as a simpler and more accurate measure for detecting hepatic steatosis in children. Further research is essential to determine the optimal role of CAP in pediatric NAFLD diagnosis and management.
The invention provides a fourteen-core ferrocene silver alkyne cluster compound, and a preparation method and application thereof, and belongs to the technical field of silver cluster compound preparation. Ferrocenylacetylene (C.ident. CFc) and silver trifluoromethane sulfonate (AgOTF) are used as raw materials, and telluric acid is used as a template, and the raw materials are mixed with tetramethylammonium hydroxide (Me)  4  NOH), a fourteen-core ferrocene silver alkyne cluster compound (hereinafter referred to as X1) was prepared. X1 belongs to tetragonal system, the space group is I-4c2, and the silver cage skeleton of the cluster compound is formed by connecting 14 silver atoms and 14 nuclear silver alkyne clusters with 12 ferrocenylethynyl and 4 acetonitrile molecules as peripheral ligands. X1 has high purity, good thermal stability and semiconductor property. X1 has good binding affinity with two cancer receptor proteins, and provides a new direction for potential pharmacological application of X1.
An information processing apparatus includes a person-involved acquisition unit and a granting unit. The person-involved acquisition unit acquires person-involved information that specifies a medical staff member who is involved in a medical procedure scheduled to be performed on a patient. The granting unit grants, to the medical staff member specified by the person-involved information, a view privilege to view a medical record of the patient. The medical record is stored in a medical record memory that stores one or more medical records. The granting unit includes a role acquisition unit and a controller. The role acquisition unit acquires role information that specifies a role of the medical staff member in the medical procedure. The controller controls a valid period of the view privilege in accordance with the role of the medical staff member specified by the role information.
Group A performed scapular stabilization exercises for 4 weeks with 2 sets of 10 repetitions. These exercises comprised of four exercise programs (Scapular retraction; Scapular mobilization, Scapular dynamic stabilization I and Scapular dynamic stabilization II).
The concentration of more than 2 ampoule amiodarone injection in 500 ml (only isotonic grape solution) is suitable. Amiodarone should be administered as far as possible via the central venous route (administered separately).
1494449 lonomycin E R SQUIBB & SONS Inc 19 Feb 1975 [11 March 1974] 7012/75 Heading C2A The invention is directed to ionomycin and salts thereof, the antibiotic having the infrared spectrum in Fig. 1 (not shown), its calcium salt having the infra-red spectrum in Fig. 2 (not shown), the following elemental analysis: C, 66À00, H, 9À17, Ca, 5À77, a melting point of 205-206 C., a molecular weight of 746, an empirical formula C 41 H 70 O 9 Ca, an ultra-violet maximum in methanol 300 nm. (E<SP>1%</SP> 1 cm  290), said salt being insoluble in methanol, ethanol, water, dilute acid and dilute alkali and being soluble in hexane, benzene, chloroform and acetone. Ionomycin is prepared by cultivating Streptomyces conglobatus ATCC 31005 in an aqueous nutrient medium comprising an assimilable carbohydrate and an assimilable nitrogen source under submerged aerobic conditions until substantial antibiotic activity is imparted to the medium. The antibiotic is crystallized in the form of its calcium salt. The free acid may be obtained by acidification of the calcium salt with a suitable acid. Other salts such as the silver, alkali metal and alkaline earth metal salts may be obtained by treating ionomycin with a suitable base.
BACKGROUND: Physical inactivity has been identified as a risk factor for multiple disorders and a strong association exists between chronic kidney disease (CKD) and a sedentary lifestyle. Even though physical activity is crucial in the development and progression of disease, the general focus of the current medical practice is the pharmacological perspective of diseases with inadequate emphasis on lifestyle intervention.
METHODS: In this narrative review we explain the pathophysiological mechanisms underlying the beneficial effects of physical exercise on CKD in addition to discussing the clinical studies and trials centred on physical exercise in patients with CKD.
RESULTS: Physical activity influences several pathophysiological mechanisms including inflammation, oxidative stress, vascular function, immune response and macromolecular metabolism. While exercise can initially induce stress responses like inflammation and oxidative stress, long-term physical activity leads to protective countermeasures and overall improved health. Trials in pre-dialysis CKD patients show that exercise can lead to reductions in body weight, inflammation markers and fasting plasma glucose. Furthermore, it improves patients' functional capacity, cardiorespiratory fitness and quality of life. The effects of exercise on kidney function have been inconsistent in these trials. In haemodialysis, peritoneal dialysis and kidney transplant patients exercise interventions improve cardiorespiratory fitness, walking capacity and quality of life. Combined training shows the best performance to increase peak oxygen uptake in haemodialysis patients. In kidney transplant recipients, exercise improves walking performance, quality of life and potentially arterial stiffness. However, exercise does not affect glucose metabolism, serum cholesterol and inflammation biomarkers. Long-term, adequately powered trials are needed to determine the long-term feasibility, and effects on quality of life and major clinical outcomes, including mortality and cardiovascular risk, in all CKD stages and particularly in kidney transplant patients, a scarcely investigated population.
CONCLUSION: Physical exercise plays a crucial role in ameliorating inflammation, oxidative stress, vascular function, immune response and macromolecular metabolism, and contributes significantly to the quality of life for patients with CKD, irrespective of the treatment and stage. Its direct impact on kidney function remains uncertain. Further extensive, long-term trials to conclusively determine the effect of exercise on major clinical outcomes such as mortality and cardiovascular risk remain a research priority.
Colestipol was given as described above. Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
ATACAND can cause symptomatic hypotension. Symptomatic hypotension is most likely to occur in patients who have been volume and/or salt depleted as a result of prolonged diuretic therapy, dietary salt restriction, dialysis, diarrhea, or vomiting. Patients with symptomatic hypotension may require temporarily reducing the dose of ATACAND, diuretic or both, and volume repletion. Volume and/or salt depletion should be corrected before initiating therapy with ATACAND.

In the CHARM program (heart failure patients), hypotension was reported in 18.8% of patients on ATACAND versus 9.8% of patients on placebo. The incidence of hypotension leading to drug discontinuation in ATACAND-treated patients was 4.1% compared with 2.0% in placebo-treated patients. In the CHARM-Added program, where candesartan or placebo was given in addition to ACE inhibitors, hypotension was reported in 22.6% of patients treated with ATACAND versus 13.8% treated with placebo [see Drug Interactions (7.3)].

Monitoring of blood pressure is recommended during dose escalation and periodically thereafter.

Major Surgery/Anesthesia 

Hypotension may occur during major surgery and anesthesia in patients treated with angiotensin II receptor antagonists, including ATACAND, due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors.
PURPOSE: To obtain a preparation producible only by mixing crushed powder and/or an extract of a crude medicine with a thicknener and water, obtainable at a low cost, having the crude medicine sterilized through the production, administrable with no water and useful for an old person, a child, etc. CONSTITUTION: This is an orally chewable preparation composed of (A) crushed powder and/or an extract of a crude medicine, (B) a thickener (preferably containing at least gelatin) and (C) water. Examples of the component A are antyusan as a gastrointestinal drug, Japanese angelica peony root powder as a treating agent for oversensitive to the cold, and HATIMIZIOUGANN and NINZINTO (both are specific prescriptions of Chinese medicine) as a nutrition robustness agent. The component A is preferably contained in the preparation at the ratio of 1-70wt.%, preferably 3-60wt.%. The component B is preferably contained in the preparation at 1-15wt.%, preferably 3-10wt.%. Water as the component C is preferably contained at 3-20 times the component B. Further, the preparation is preferably administered at 1-20g/dose, preferably 5-14g/dose 1-3 times a day.
Dextrose Injection is for admixture with amino acids or dilution with other compatible intravenous fluids. It is not for direct intravenous infusion. Administer solutions containing more than 5% dextrose or with an osmolarity of ≥ 900 mOsm/L through a central vein [see Dosage and Administration (2.1)]. The infusion of hypertonic solutions into a peripheral vein may result in vein irritation, vein damage, and/or thrombosis. The primary complication of peripheral access is venous thrombophlebitis, which manifests as pain, erythema, tenderness or a palpable cord. Remove the catheter as soon as possible, if thrombophlebitis develops.
WARNING: If you have sudden or severe pain in your lower abdomen or stomach area, you may have an ectopic pregnancy or an ovarian cyst. If this happens, you should contact your doctor or clinic immediately.

1\. Ectopic pregnancy. An ectopic pregnancy is a pregnancy outside the womb. Because POPs protect against pregnancy, the chance of having pregnancy outside the womb is very low. If you do get pregnant while taking POPs, you have a slightly higher chance that the pregnancy will be ectopic than do users of some other birth control methods.

2\. Ovarian cysts. These cysts are small sacs of fluid in the ovary. They are more common among POP users than among users of most other birth control methods. They usually disappear without treatment and rarely cause problems.

3\. Cancer of the reproductive organs and breasts. Some studies in women who use combined oral contraceptives that contain both estrogen and a progestin have reported an increase in the risk of developing breast cancer, particularly at a younger age and apparently related to duration of use. There is insufficient data to determine whether the use of POPs similarly increases this risk.

Some studies have found an increase in the incidence of cancer of the cervix in women who use oral contraceptives. However, this finding may be related to factors other than the use of oral contraceptives and there is insufficient data to determine whether the use of POPs increases the risk of developing cancer of the cervix.

4\. Liver tumors. In rare cases, combined oral contraceptives can cause benign but dangerous liver tumors. These benign liver tumors can rupture and cause fatal internal bleeding. In addition, a possible but not definite association has been found with combined oral contraceptives and liver cancers in studies in which a few women who developed these very rare cancers were found to have used combined oral contraceptives for long periods of time. There is insufficient data to determine whether POPs increase the risk of liver tumors.
Oral poliovirus vaccine (OPV) cessation is essential to achieve eradication of polio as OPV contains live poliovirus, which can mutate and become neurovirulent. After OPV cessation, inactivated poliovirus vaccine (IPV) will be the only polio vaccine used for routine immunization. This clinical trial will provide poliovirus type-specific immunogenicity data on an IPV or fractional-dose IPV (fIPV)-only schedule for routine immunization, which will be important for post OPV cessation era. For fIPV, it will provide immunogenicity data on fIPV administered either intradermally (ID) or intramuscularly (IM) and allow a direct comparison of the two methods.

Healthy infants 6 weeks of age will be enrolled at two study clinics in Dhaka, Bangladesh, and randomized to one of seven study arms. Infants will be followed-up until 10 months of age through clinic visits. Blood specimens will be collected to test for immunological response.
ABSTRACT      A human endogenous cancer regulatory factor (KBS) having a molecular weight of 82,000 + 10,000 and an isoelectric point of pH 6.5 + 0.5, a process for preparing KBS and a pharmaceutical composition containing KBS are disclosed.  The KBS of the present invention is useful as a potent tumoricidal or anti-tumor agent.     TITLE OF THE INVENTION      Human endogenous cancer regulatory factor, process for preparing the same, pharmaceutical composition containing the same and human monocytic leukemia cell lines FIELD OF THE INVENTION    The present invention relates to a novel human endogenous cancer regulatory factor, a process for preparing the same, a pharmaceutical composition containing the same, and human monocytic leukemia cell lines.                   BACKGROUND OF THE INVENTION    While several biologically active materials are known to have anti-tumor activities, interferons and tumor necrosis factor (TNF) are most popular. The latter is a proteinic, biologically active material produced by animals, and it is said that unlike interferons, TNF has trans-species potent tumoricidal or anti-tumor activities.          Furthermore, the TNY is believed to act on tumor cells both directly and indirectly through the mechanism of immunization  in the host.    TNF was first discovered in mice by Old et a1. in 1975 at Sloan-Kettering Institute for Cancer Research, U.S.A., and it was later reported by Carswell et al. as a material capable of causing tumor necrosis [Proc. Nat. Acad. Sci.          USA, 72, No. 9, pp. 3666-3670 (1975)].          Methods of purifying TNFS (i.e. mouse TNF and rabbit TNF)
OBJECTIVE: The objective is to describe the experiences and perceptions of caregivers who participated in a community systems navigator intervention that addressed unmet social needs.
DESIGN, SETTING AND PATIENTS: A qualitative descriptive study with caregivers of children enrolled in a clinical trial addressing unmet social needs of families with children cared for in a tertiary pediatric weight management clinic, through community systems navigation. Participants were asked open-ended questions related to perceptions of social needs screening in clinical settings. Interviews were recorded and analysed using Braun and Clarke's six-phase approach to thematic analysis.
RESULTS: Ten parent participants were interviewed. Social needs screening perception and acceptability varied between participants. Social needs screening was comfortable for most but stressful for others. Participants noted that trusting relationships promote comfort with sharing social needs information, and this data should be shared on the electronic health record if accurate and purposeful. They found the online screening tool convenient but thought it could also limit opportunities to elaborate. Some participants noted the intervention of community systems navigation helpful; however, others described the need for more tailored resources.
CONCLUSIONS: Screening for unmet social needs in clinical settings is complex and should be family centred, including the consideration of the mode of screening, data sharing in the electronic health record and ensuing interventions. Perspectives of families should drive the design of future larger scale community navigation interventions to address unmet social needs in clinical settings.
Electrosurgery, also known as thermal cautery, refers to a process in which a direct or alternating current is passed through a resistant metal wire electrode, generating heat. The heated electrode is then applied to living tissue to achieve hemostasis or varying degrees of tissue destruction. It is commonly used for tonsillectomy and adenoidectomy in pediatric patients. The electrocautery setting will be standardized to 12 for tonsils and 30 for adenoids.
Human menopausal gonadotrophin IM daily was administrated from day 2 of the cycle. The Gonadotropins releasing hormone antagonist GnRH ant (Cetrotide, Serono, Geneva, Switzerland) was given when the leading follicle was from 12 to 14 mm, at a daily dose of 0.25 mg SC.
Several methods and apparatuses for determining whether a vaccine specimen has previously frozen. One method includes providing a known value correlating to the settling of vaccine known to have previously frozen, and, upon agitation of the specimen, directing light substantially through the specimen as the specimen settles. The amount of light that passes through the specimen correlates to the settling of the specimen and is compared to the known value to determine whether the specimen has previously frozen. Another method includes providing light of a predetermined wavelength and directing the light through the specimen. The intensity of the light transmitted through the specimen is compared to the intensity of light of the predetermined wavelength having passed through an amount of vaccine known to have previously frozen. Based on this comparison, a determination is made whether the specimen has previously frozen.
The method, and the apparatus for carrying out the steps of the method, are utilized in the centrifugal liquid processing of whole blood wherein whole blood is withdrawn from a donor, passed through a fluid system and the blood is centrifuged to separate the same into at least three components. One component which is to be collected is withdrawn at a fixed rate of volumetric displacement while the other two components are withdrawn at variable rates of volumetric displacement. The other two components are recombined and returned to the donor. The withdrawal of the one component is optically monitored to determine whether or not either one of the other components is being mixed with the one component. When such a mixing is sensed, the rate of withdrawal of one of the other two components is increased while the rate of withdrawal of the other components is decreased thereby to ensure withdrawal of the desired one component, e.g., white blood cells with minimal contamination thereof with the other two components, e.g., red blood cells and plasma containing platelets. A given amount of the one component withdrawn is collected in a receptacle.
HIV prevention is a global public health priority. Providing efficacious prevention methods that have the greatest likelihood of use will have a profound impact on the public's health. Critical to their use is "acceptability." However, current conceptualizations of adherence and acceptability fail to fully articulate and account for patterns of use and non-use. Formulation properties are critically important to both drug delivery and the user experience. Microbicide developers thus have the opportunity to directly control a formulation's impact on acceptability and adherence to product use, as well as biological product performance. Microbicide products can and should be developed such that they achieve performance standards for both these behavioral (user experience) and biological (efficacy) functions. By incorporating the user experience early on in the product development process, developers will have the greatest chance of providing at-risk individuals with the best prevention methods science can provide. Developing prevention products that can be used in the vagina and/or the rectum and that optimize the user experience in both compartments increases the likelihood that these products will be used consistently and correctly. The impact on global public health has the potential to be far-reaching, decreasing HIV and sexually transmitted infections (STI) incidence and prevalence in both women and men.

Methodology and Data Collection: This is a formative mixed methods design in which volunteers (N\~20-30; \~10-15 males; \~10-15 females) will first be prescreened for basic study eligibility using a brief questionnaire. Those who are interested in the study and are eligible based on their responses to the prescreen will then complete a STI/HIV screening and pregnancy test (for females).

During the course of the study, participants will evaluate 3 products: 2 distinct suppository formulations and 1 gel formulation that represent a range of rheological and other biophysical properties of potential microbicides being designed for rectal/dual compartment use. Participants will evaluate the experience of suppository use (as compared to gel use) in the context of receptive anal intercourse (RAI) among males and females, and in the context of vaginal intercourse (VI) (females). Each participant will be randomly assigned to the order in which they will evaluate the 3 products. Participants will be required to complete a brief phone survey (\<3 minutes) every day, beginning the day after they start their first product evaluation period and continuing until they complete their final study visit (approximately 10-20 weeks). The phone survey includes a short set of questions about sexual behavior and product use during the time since the last phone survey (about 24 hours). After a sexual encounter that includes RAI/VI and study product use, participants will be required to complete a web survey about their experience with the study product. After a participant has evaluated all three products, participants complete an individual in-depth interview with study staff about their experiences with the study products.